LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Abierto

Sector Salud

1,157.42 0.38

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1151.73

Máximo

1160.91

Métricas clave
By Trading Economics
Ingresos	710M 1.4B
Ventas	400M 3.6B
P/B Media del Sector	31.03 103.001
BPA	11.56
Margen de beneficio	40.346
Empleados	13,450
EBITDA	933M 1.8B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+2.78 upside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	130B
Apertura anterior	1157.04
Cierre anterior	1157.42

Noticias sobre sentimiento de mercado

By Acuity

59%

41%

284 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

1143.245 / 1162.865 Soporte y Resistencia

Regeneron Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

8 jul 2024, 12:00 UTC

Ganancias

Regeneron Expects Earnings Hit After $24 Million R&D Charge

2 may 2024, 11:02 UTC

Ganancias

Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales

2 feb 2024, 11:59 UTC

Ganancias

Regeneron's 4Q Sales Edge Higher, Despite Softening Demand for Covid Products

1 ago 2024, 11:50 UTC

Ganancias

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 ago 2024, 10:37 UTC

Ganancias

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 ago 2024, 10:30 UTC

Ganancias

Regeneron Pharma 2Q EPS $12.41 >REGN

1 ago 2024, 10:30 UTC

Ganancias

Regeneron Pharma 2Q Net $1.43B >REGN

1 ago 2024, 10:30 UTC

Ganancias

Regeneron Pharma 2Q Rev $3.55B >REGN

20 jun 2024, 20:16 UTC

Principales Noticias

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 jun 2024, 18:09 UTC

Principales Noticias

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 jun 2024, 11:00 UTC

Principales Noticias

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

2 may 2024, 10:32 UTC

Ganancias

Regeneron Pharma Cuts 2024 Capital Spending View to $780M-$880M From $825M-$950M >REGN

2 may 2024, 10:32 UTC

Ganancias

Regeneron Pharma Still Sees 2024 Adjusted Gross Margin 89%-91% >REGN

2 may 2024, 10:31 UTC

Ganancias

Regeneron Pharma Sets New $3 Billion Share-Repurchase Program >REGN

2 may 2024, 10:30 UTC

Ganancias

Regeneron Pharma 1Q Rev $3.15B >REGN

2 may 2024, 10:30 UTC

Ganancias

Regeneron Pharma 1Q Adj EPS $9.55 >REGN

2 may 2024, 10:30 UTC

Ganancias

Regeneron Pharma 1Q EPS $6.27 >REGN

2 may 2024, 10:30 UTC

Ganancias

Regeneron Pharma 1Q Net $722M >REGN

11 abr 2024, 13:47 UTC

Acciones populares

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands -- WSJ

5 feb 2024, 12:00 UTC

Principales Noticias

What a $200 Billion Blockbuster Drug Reveals About Big Pharma's Playbook -- Heard on the Street -- WSJ

2 feb 2024, 17:05 UTC

Ganancias

Regeneron Earnings Beat Forecasts as Sales of Updated Eye Drug Raise Hopes -- Barrons.com

2 feb 2024, 14:13 UTC

Ganancias

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High -- IBD

2 feb 2024, 11:36 UTC

Ganancias

Regeneron Pharma Sees 2024 Capital Spending $825M-$950M >REGN

2 feb 2024, 11:36 UTC

Ganancias

Regeneron Pharma Sees 2024 Adjusted Gross Margin 89%-91% >REGN

2 feb 2024, 11:36 UTC

Ganancias

Regeneron Pharma Sees 2024 Adjusted R&D Spending $4.3B-$4.5B >REGN

2 feb 2024, 11:31 UTC

Ganancias

Regeneron Pharma: 4Q Dupixent Global Sales, Recorded by Sanofi, Rose 31% to $3.22B >REGN

2 feb 2024, 11:31 UTC

Ganancias

Regeneron Pharma 4Q U.S. Eylea HD, Eylea Sales $1.46B >REGN

2 feb 2024, 11:30 UTC

Ganancias

Regeneron Pharma 4Q EPS $10.19 >REGN

2 feb 2024, 11:30 UTC

Ganancias

Regeneron Pharma 4Q Rev $3.43B >REGN

2 feb 2024, 09:37 UTC

Ganancias

These Stocks Are Moving the Most Today: Meta, Amazon, Apple, Intel, Deckers, Skechers, Clorox, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Regeneron Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

2.78% repunte

Estimación a 12 meses

Media 1,185.39 USD 2.78%

Máximo 1,300 USD

Mínimo 870 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Regeneron Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

Comprar

Mantener

Vender

De acuerdo con 20 analistas que ofrecen calificaciones bursátiles a para Regeneron Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1143.245 / 1162.865Soporte y Resistencia

Recent bullish events outweigh bearish events.

There is one bullish event.

There are no events.

Sentimiento

By Acuity

284 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.